Drug Trial Radar · NCT05417594
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
695
Planned (sponsor's estimate)
Start
Jun 24, 2022
Primary completion
Feb 7, 2028
Study completion Feb 7, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.
Conditions
- Advanced Solid Malignancies
Interventions
AZD9574Drug
Participants will receive AZD9574 orally.
Temozolomide (TMZ)Drug
Participants will receive temozolomide orally.
[11C]AZ1419 3391Drug
Participants will receive \[11C\]AZ1419 3391 intravenously.
Trastuzumab Deruxtecan (T-DXd)Drug
Participants will receive T-DXd intravenously.
Datopotamab Deruxtecan (Dato-DXd)Drug
Participants will receive Dato-DXd intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs), and Serious Adverse Events (SAEs)Time frame: From first dose to post-treatment follow-up (approximately three years)
- Changes from baseline in laboratory findings, electrocardiograms (ECGs), and vital signsTime frame: From last assessment prior to first dose to post-treatment follow up visit (approximately three years)
- Change from baseline Eastern Cooperative Oncology Group performance status (ECOG PS)Time frame: From last assessment prior to first dose to post-treatment follow up visit (approximately three years)
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: Cycle 0 and Cycle 1 (Day 1 to Day 35)
Locations
32 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California · Withdrawn
Research Site
Los Angeles, California · Recruiting
Research Site
San Francisco, California · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Recruiting
Research Site
Portland, Oregon · Withdrawn
Research Site
Houston, Texas · Recruiting
Research Site
San Antonio, Texas · Recruiting
Research Site
Richmond, Virginia · Withdrawn
Research Site
Darlinghurst, Australia · Recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Randwick, Australia · Recruiting
Research Site
Bayern, Germany · Withdrawn
Research Site
Berlin, Germany · Withdrawn
Research Site
Heidelberg, Germany · Withdrawn
Research Site
Mainz, Germany · Withdrawn
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
A Coruña, Spain · Recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
Málaga, Spain · Recruiting
Research Site
Pozuelo de Alarcón, Spain · Recruiting
Research Site
Sant Cugat del Vallès, Spain · Recruiting
Research Site
Seville, Spain · Recruiting
Research Site
Lund, Sweden · Recruiting
Research Site
Stockholm, Sweden · Recruiting
Research Site
Glasgow, Scotland, United Kingdom · Recruiting
Research Site
London, United Kingdom · Recruiting
Research Site
Newcastle upon Tyne, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.